title: The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines.
abstract: Synthetic oligodeoxynucleotides containing CpG immunostimulatory sequences (ISS) have been shown to act as potent adjuvants of type 1 immune responses when co-administered with protein or peptide vaccines. We have recently shown that ISS can increase the anti-polysaccharide (CHO) and anti-tetanus toxoid (TT) or anti-diphtheria (CRM) toxoid antibody levels if used as adjuvant of anti-Haemophilus influenzae type b (Hib) CHO vaccine conjugated with TT or CRM. The analysis of anti-TT and anti-CRM IgG subclasses showed a significant increase in IgG2a, IgG2b and/or IgG3 in the presence of ISS. Anti-TT and anti-CRM antibodies were shown to neutralize the activity of both the tetanus and diphtheria toxin in vivo or in vitro tests respectively. These data show that ISS have the potential to increase host antibody response against both the CHO and the protein component of a conjugated vaccine, and encourage the investigation to identify strategies of vaccination with schedules aimed at the valuation of protein carriers as protective immunogens.
authors: Laboratorio di Batteriologia e Micologia Medica, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
authors: C
authors: C
authors: von Hunolstein
authors: S
authors: S
authors: Mariotti
authors: R
authors: R
authors: Teloni
authors: G
authors: G
authors: Alfarone
authors: G
authors: G
authors: Romagnoli
authors: G
authors: G
authors: Orefici
authors: R
authors: R
authors: Nisini
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D016667:Bacterial Capsules; D001483:Base Sequence; D018899:CpG Islands; D004168:Diphtheria Toxoid / Q000008:administration & dosage; D005260:Female; D006001:Glycoconjugates / Q000008:administration & dosage / Q000276:immunology; D018073:Haemophilus Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006193:Haemophilus influenzae / Q000276:immunology*; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000145:classification; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage* / Q000235:genetics; D011135:Polysaccharides, Bacterial / Q000276:immunology; D013745:Tetanus Toxoid / Q000008:administration & dosage
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D004168:Diphtheria Toxoid; D006001:Glycoconjugates; D018073:Haemophilus Vaccines; C055753:Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate; C044237:Haemophilus influenzae type b polysaccharide vaccine; C052180:Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate; D007074:Immunoglobulin G; D009838:Oligodeoxyribonucleotides; D011135:Polysaccharides, Bacterial; D013745:Tetanus Toxoid